Published in Pharma Investments, Ventures and Law Weekly, November 15th, 2009
"As we continue to pursue strategic alternatives, we are pleased that the majority of our unsecured note holders have converted $537,000 of their notes and $109,587 of accrued interest into common stock of the Company," said Urigen's CFO Martin E. Shmagin. "We are also pleased that our lead institutional investor, Platinum-Montaur Life Sciences LLC, has agreed to a six month extension on the maturity of our secured debt." About Urigen...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly